Clinical Trials Logo

Lung Non-Small Cell Carcinoma clinical trials

View clinical trials related to Lung Non-Small Cell Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06427369 Not yet recruiting - Clinical trials for Lung Non-Small Cell Carcinoma

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

Start date: September 1, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of 124I-hJAA-F11, and evaluates how well it works in diagnosing lung cancer. 124I-hJAA-F11 uses a known radioactive substance used in imaging called iodine 124 (124I). hJAA-F11 is an experimental (investigational) antibody that is currently being evaluated as a potential treatment for lung cancer. In animal studies, hJAA-F11 has shown anti-tumor activity against tumors bearing the Thomsen-Friedenreich antigen that is found in over 90% of lung cancers. 124I-hJAA-F11 has the 124I radioactive dye attached to this investigational antibody, which may be a potential tool for imaging-based diagnosis of lung cancer.

NCT ID: NCT06418204 Not yet recruiting - Melanoma Clinical Trials

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

COSMIC
Start date: August 2024
Phase:
Study type: Observational

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

NCT ID: NCT06116682 Not yet recruiting - Clinical trials for Lung Non-Small Cell Carcinoma

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Start date: July 16, 2024
Phase: Phase 2
Study type: Interventional

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-vmjw works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-vmjw is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-vmjw may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.